



May 10, 2022

Notice regarding Cancellation of “Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year”

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka, Japan; hereinafter, “Santen” or the “Company”) announced today that its Board of Directors has cancelled the transition to a holding company structure through sole-share transfer with effect from April 1, 2022, and the change of Santen’s fiscal year period starting Jan 1, 2022 (hereinafter, the “Transition”), which was previously resolved and announced on February 4, 2021 and subsequently postponed and announced on May 11, 2021.

1. Background

The Company announced the postponement of the Transition last year resulting from a comprehensive assessment of short-term changes in its business environment after preparations for the Transition were underway to allow Santen to achieve steadily its long-term vision, Santen 2030. Subsequent considerations has led the Company to resolve the cancellation of the Transition to allow its currently effective organization to promptly address improvements in profitability for a sustainable growth trajectory as presented in the medium-term plan (Medium-Term Plan 2025).

Santen announced its new Executive Management Team (hereinafter, “EMT”) effective on April 1, 2022 as part of the importance placed on strengthening our business execution capabilities. With the reinvention of our leadership team, Business Heads in Regions and Business groups and Centers of Excellence (CoE), which lead strategies and operations from global perspective, will collaborate to establish a global management system that enables fast and effective decision-making and strengthen the governance system for business execution.

Santen aims to bolster its competitiveness as a global company and strengthen its strategic execution capabilities with our organization leveraging EMT.

2. Financial impact

The above-mentioned cancellation will not impact consolidated earnings results for the year ending March 31, 2023.

Contact:

Guillaume Sakuma

Global Head of IR, IR Group

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen’s website (<https://www.santen.com/en/>) .